235 related articles for article (PubMed ID: 12100691)
21. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
22. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
23. [The Sézary syndrome].
Ferreira F; Correia TM; Callabro L; Andrade J
Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.
Kuzel TM; Hurria A; Samuelson E; Tallman MS; Roenigk HH; Rademaker AW; Rosen ST
Blood; 1996 Feb; 87(3):906-11. PubMed ID: 8562961
[TBL] [Abstract][Full Text] [Related]
25. Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody).
Osborne GE; Pagliuca A; Ho A; du Vivier AW
Br J Dermatol; 2006 Sep; 155(3):617-20. PubMed ID: 16911291
[TBL] [Abstract][Full Text] [Related]
26. Bexarotene monotherapy for patients with refractory Sézary syndrome.
Staib G; Scharffetter-Kochanek K
Dermatol Clin; 2008 Jan; 26 Suppl 1():61-3. PubMed ID: 18405190
[No Abstract] [Full Text] [Related]
27. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia.
Rossini MS; de Souza EM; Cintra ML; Pagnano KB; Chiari AC; Lorand-Metze I
J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):538-42. PubMed ID: 15324388
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
Bagot M
Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
[No Abstract] [Full Text] [Related]
30. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Robak T
Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
[TBL] [Abstract][Full Text] [Related]
31. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
32. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
[TBL] [Abstract][Full Text] [Related]
33. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
34. 2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature.
Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Hellmann A
Med Sci Monit; 2000; 6(4):740-5. PubMed ID: 11208402
[TBL] [Abstract][Full Text] [Related]
35. [Clinicomorphological characteristics of Sezary's disease and mycosis fungoides].
Vinogradova IuE; Giliazitdinova EA; Zamulaeva IA; Zybunova EE; Kaplanskaia IB; Kravchenko SK; Kremenetskaia AM; Lutsenko IN; Samoĭlova RS; Selivanova EN; Sidorova IuV; Shklovskiĭ-Kord NE
Ter Arkh; 2005; 77(10):61-5. PubMed ID: 16320688
[TBL] [Abstract][Full Text] [Related]
36. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
[TBL] [Abstract][Full Text] [Related]
37. Bexarotene combination therapy for patients with Sézary syndrome.
Ranki A
Dermatol Clin; 2008 Jan; 26 Suppl 1():55-7. PubMed ID: 18405189
[No Abstract] [Full Text] [Related]
38. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders.
Kong LR; Samuelson E; Rosen ST; Roenigk HH; Tallman MS; Rademaker AW; Kuzel TM
Leuk Lymphoma; 1997 Jun; 26(1-2):89-97. PubMed ID: 9250792
[TBL] [Abstract][Full Text] [Related]
39. [Clinical pharmacology of 2-chlorodeoxyadenosine (Cladribine)].
Góra-Tybor J; Robak T
Przegl Lek; 1996; 53(8):614-8. PubMed ID: 8999463
[TBL] [Abstract][Full Text] [Related]
40. Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndrome.
Bouwhuis SA; el-Azhary RA; Gibson LE; McEvoy MT; Pittelkow MR
J Am Acad Dermatol; 2002 Jul; 47(1):63-7. PubMed ID: 12077583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
